Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q6IQ20
UPID:
NAPEP_HUMAN
Alternative names:
-
Alternative UPACC:
Q6IQ20; Q5CZ87; Q769K1
Background:
The N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D is a pivotal enzyme in lipid metabolism, catalyzing the hydrolysis of N-acyl-phosphatidylethanolamines to produce bioactive molecules. Its role in generating long-chain saturated and monounsaturated N-acylethanolamines in the brain underscores its importance in neural function and lipid homeostasis.
Therapeutic significance:
Understanding the role of N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D could open doors to potential therapeutic strategies. Its involvement in lipid metabolism and neuron survival, particularly through RAC1 activation, highlights its potential as a target in treating metabolic and neurodegenerative diseases.